tetramethylpyrazine has been researched along with Cancer of Ovary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, S; Xia, L; Zhang, H | 1 |
| Chen, WJ; He, JL; Li, WM; Liu, HT; Liu, HZ; Wang, YX; Yang, Z; Yin, J; Yu, C | 1 |
2 other study(ies) available for tetramethylpyrazine and Cancer of Ovary
| Article | Year |
|---|---|
Ligustrazine inhibits the proliferation and migration of ovarian cancer cells via regulating miR-211.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Ovarian Neoplasms; Pyrazines | 2021 |
Tetramethylpyrazine inhibits migration of SKOV3 human ovarian carcinoma cells and decreases the expression of interleukin-8 via the ERK1/2, p38 and AP-1 signaling pathways.
Topics: Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Coculture Techniques; Female; Genes, Reporter; Humans; Interleukin-8; Luciferases; Mitogen-Activated Protein Kinases; Monocytes; Ovarian Neoplasms; Phosphorylation; Pyrazines; Signal Transduction; Transcription Factor AP-1; Transcription, Genetic | 2011 |